Navigation Links
Isis Reports Financial Results and Highlights for Second Quarter of 2008
Date:8/7/2008

ted collaboration with GSK. As part of Regulus' strategic alliance with GSK, Regulus received a $15 million upfront fee, which it began amortizing into revenue in the second quarter of 2008 and will continue to amortize over its six-year period of performance under the agreement.

Excluding non-cash compensation expense related to stock options, operating expenses for Regulus were $1.8 million and $3.0 million for the three and six months ended June 30, 2008. With the recently announced strategic alliance with GSK, it is anticipated that Regulus' expenses will increase as Regulus continues to advance its research and development activities. The GSK alliance enhances Regulus' ability to expand operations and advance its programs. Regulus generated a loss from operations, excluding non-cash compensation expense related to stock options, of $1.2 million and $2.2 million for the three and six months ended June 30, 2008. Regulus' non-cash compensation expense related to stock options was $681,000 and $1.1 million for the three and six months ended June 30, 2008. Because Regulus was formed in the third quarter of 2007, it did not have operating results in the first half of 2007.

Quarterly Highlights

"Since the completion of our Genzyme collaboration, we've made great progress with mipomersen by initiating the first of four studies scheduled to begin by year end and receiving a patent allowance that gives the Isis-Genzyme Apolipoprotein B franchise broad protection of mipomersen and other antisense apoB compounds. In addition to the successes of our partnered drugs and satellite companies in the first half of the year, we continue to maximize the economic potential of our business model and our technology, while enabling the advancement of a broad portfolio of both partnered and internally developed drugs," concluded Ms. Parshall.

Cardiovascular Program

-- Completed licensing transaction for mipomersen

-- Finalized and announ
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
2. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
3. Caliper Life Sciences Reports Second Quarter 2008 Results
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. EntreMed Reports Second Quarter 2008 Financial Results
6. Transgenomic Reports Second Quarter 2008 Results
7. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
8. Bionovo Reports Second Quarter 2008 Financial Results
9. AtriCure Reports Record Second Quarter 2008 Financial Results
10. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
11. eResearchTechnology Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 Histogen, Inc., a ... of cells grown under simulated embryonic conditions, today announced ... with Suneva Medical, Inc. for physician-dispensed aesthetic products containing ... , This agreement is an amendment to the existing ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, today ... In this role, Michelle will work with current and potential ... development of iLab products. Her main goal will be to ... scientific community by offering the most advanced, user-friendly, and high-impact ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Global ... developing innovative information technology solutions for patients, physicians, ... care stakeholders, announced today the signing of a ... Food and Drug Administration (FDA). This initiative ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... ATLANTA, Sept. 5 CryoLife, Inc. (NYSE: ... company, announced,today that D. Ashley Lee, executive vice ... CryoLife, Inc., is scheduled to present at,the Bear ... 10,2007 at 4:30 p.m. EDT. Mr. Lee will ...
... Therapy Regulatory Consultant and Cryopreservation Expert, BOTHELL, ... Board: BLFS), a leading developer and marketer of,proprietary ... and organs, today announced the expansion of its ... leading experts in cell,therapy quality and regulatory assurance ...
... today at European Society of Cardiology Congress ... ... Therapeutics,Inc. (Nasdaq: CVTX ) announced today that data published in Circulation ... that Ranexa(R) (ranolazine extended-release tablets) reduced,both ventricular and atrial arrhythmias in patients ...
Cached Biology Technology:BioLife Solutions Expands Scientific Advisory Board 2BioLife Solutions Expands Scientific Advisory Board 3BioLife Solutions Expands Scientific Advisory Board 4Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R) 2Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R) 3Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R) 4
(Date:4/18/2014)... years, researchers have published soil organic carbon sequestration rates. ... soil organic carbon can be sequestered by simply switching ... However, there is a growing body of research with ... without cover crops, small grains, and forages may not ... rates. , "Some studies have shown that both moldboard ...
(Date:4/18/2014)... team of researchers led by a University of California, ... a $7.5 million Department of Defense grant to uncover ... foundations for the predictable design of light-weight, tough and ... structures from plants and animals, including the mantis shrimp, ... systems have constructed over millions of years and coming ...
(Date:4/17/2014)... there was a word for chili peppers. Information about ... with a study of the appearance of words for ... where jalapeos were domesticated and highlight the value of ... Kraft et al.) of nine papers presented in a ... National Academy of Sciences on plant and animal ...
Breaking Biology News(10 mins):Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4Mantis shrimp, toucan and trilobite, oh my 2Mantis shrimp, toucan and trilobite, oh my 3Chickens to chili peppers 2Chickens to chili peppers 3
... Hurricane Ike roared ashore in Texas, more than two ... to preserve food and others looking for ways to ... some instances, poisonous. Researchers at The University of Texas ... of children treated for carbon monoxide poisoning caused by ...
... The Society for Prevention Research (SPR) will hold its ... 400 New Jersey Avenue, NW, Washington, D.C., 20001. ... embargo. Reporters can reach authors by registering (free) for ... call 703-615-2466 to schedule media interviews anytime during the ...
... can dock with each other to create a gap junction ... the Journal of General Physiology ( JGP ), ... new research that provides insight into how hemichannels are kept ... how they open in certain conditions as part of a ...
Cached Biology News:Pediatric carbon monoxide poisoning linked to video games after Hurricane Ike 2Society for Prevention Research Meeting in Washington, D.C., May 27-29, 2009 2Society for Prevention Research Meeting in Washington, D.C., May 27-29, 2009 3
...
... Antibody Modification Services ,,GenScript ... antibody labeling and antibody fragmentation. Labeling ... signals for visualization and quantitation of ... it is preferable to use only ...
Attoglow Western Blot Enhancing Kit contains Millennium Enhancer which can significantly boost Western blot signals, and is compatible with other enhancing mechanisms to achieve multiplied enhancing ...
Immunogen: Synthetic peptide: S(399) P W S E L E F Q F P D D K D P V W E F(418) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: